Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Form 8 (OPD) Evolution/Canaccord

5 Sep 2011 16:55

RNS Number : 6614N
Evolution Group PLC
05 September 2011
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

The Evolution Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each party to the offer

Canaccord Financial Inc

(d) Is the party to the offer making the disclosure the offeror or the offeree?

OFFEREE

(e) Date position held:

2 September 2011

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES

If YES, specify which:

Investec plc

The Evolution Group plc

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

0

0

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

 

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

RBC Capital Markets is broker to the Evolution Group plc. The following entities are part of the same group as RBC Capital Markets

RBC Global Asset Management Inc

Discretionary Clients Position

Long position: 4,128,853 ordinary shares

Short position: 47,500 ordinary shares

 

Held by RBC Dominion Securities IncLong - 1503 shares (held via a derivative other than an option)Short - 1503 ordinary shares

 

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

5 September 2011

Contact name:

Tony Lee

Telephone number:

020 7071 4300

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEUVVVRASAKRAR
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.